We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

SEROSEP

Serosep Ltd. is one of Ireland’s leading diagnostics specialists and an innovative, specialist partner of choice for ... read more Featured Products: More products

Download Mobile App





Serosep Exhibits EntericBio System for Testing, Detecting and Identifying GI Pathogens at MEDICA 2022

By LabMedica International staff writers
Posted on 14 Nov 2022

Serosep Ltd. More...

(Limerick Ireland) is exhibiting its unique system that is revolutionizing molecular testing of gastrointestinal (GI) pathogens at the MEDICA 2022 International Trade Fair being held on November 14-17 in Düsseldorf, Germany. MEDICA is the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals.

At MEDICA 2022, Serosep is exhibiting its EntericBio system which is the market leader in GI realtime PCR testing in the UK/Ireland and provides medium/high throughput labs with a rapid, reliable and easy to use solution for their enteric pathogen testing needs. The EntericBio system is unique as it is capable of detecting target DNA and RNA directly from stool specimens, circumventing the requirement for commercial nucleic acid extraction purification and minimizes hands on time for the laboratory personnel. The EntericBio system provides a complete and flexible modular menu for testing, detecting and identifying GI pathogens including bacteria, parasites, CPE and viruses within the same work-flow and platform with a result for up to 46 specimens per run in les than three hours and results for consecutive runs each hour.

Serosep is also highlighting its comprehensive range of pre-filled Histopot specimen containers for use in histology and pathology laboratories. These biopsy sample containers are manufactured to the highest standard, using quality state of the art production techniques, in a certified manufacturing facility. The HistoPot ensures the safety during patients’ biopsy sample fixation, which is the single most important stage in the histopathology process. The HistoPot is regarded as one of the benchmarks for the fixation and transportation of millions of critical histological samples worldwide.

Related Links:
Serosep Ltd.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
HPV Test
Allplex HPV28 Detection
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

CAP Updates Cancer Protocols to Refine Breast Cancer Biomarker Reporting and GIST Molecular Testing

Standardized biomarker reporting and molecular profiling are central to pathology-driven cancer care, but evolving practices require laboratories to keep reporting templates current. These templates capture... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.